Candel Therapeutics (CADL) Non-Current Debt (2020 - 2025)
Candel Therapeutics (CADL) posted Non-Current Debt of $1.0 million for Q4 2025, up 3.6% sequentially from $973000.0 in Q3 2025, and down 41.83% YoY from $1.7 million in Q4 2024.
Candel Therapeutics (CADL) Non-Current Debt (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Non-Current Debt for 6 years, with the latest figure at $1.0 million in Q4 2025.
- Quarterly Non-Current Debt fell 41.83% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (down 41.83% YoY) and the FY2025 annual result came in at $1.0 million, down 41.83% from the prior year.
- Non-Current Debt grew to $1.0 million in Q4 2025 per CADL's latest filing, from $973000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $20.2 million in Q4 2022 and troughed at $521000.0 in Q2 2021.
- A 5-year average of $6.6 million and a median of $990500.0 in 2025 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt surged 3743.76% in 2022, then slumped 96.5% in 2023.
- Over 5 years, Non-Current Debt stood at $560000.0 in 2021, then soared by 3507.5% to $20.2 million in 2022, then slumped by 96.28% to $751000.0 in 2023, then soared by 130.76% to $1.7 million in 2024, then slumped by 41.83% to $1.0 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.0 million, $973000.0, and $904000.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 973,000.00 |
| Mar 31, 2025 | 904,000.00 |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | 840,000.00 |
| Jun 30, 2024 | 6.71 Mn |
| Mar 31, 2024 | 9.17 Mn |
| Dec 31, 2023 | 751,000.00 |
| Sep 30, 2023 | 14.34 Mn |
| Jun 30, 2023 | 700,000.00 |
| Mar 31, 2023 | 19.02 Mn |
| Dec 31, 2022 | 20.20 Mn |
| Sep 30, 2022 | 626,000.00 |
| Jun 30, 2022 | 20.03 Mn |
| Mar 31, 2022 | 19.94 Mn |
| Dec 31, 2021 | 560,000.00 |
| Sep 30, 2021 | 541,000.00 |
| Jun 30, 2021 | 521,000.00 |
| Dec 31, 2020 | 483,000.00 |